By a News Reporter-Staff News Editor at Clinical Trials Week -- Fresh data on Ascites are presented in a new report. According to news reporting from Cambridge, Massachusetts, by NewsRx journalists, research stated, "Ascites tumor cells (ATCs) represent a potentially valuable source of cells for monitoring treatment of ovarian cancer as it would obviate the need for more invasive surgical biopsies. The ability to perform longitudinal testing of ascites in a point-of-care setting could significantly impact clinical trials, drug development, and clinical care."
The news correspondents obtained a quote from the research from the Massachusetts Institute of Technology, "Here, we developed a microfluidic chip platform to enrich ATCs from highly heterogeneous peritoneal fluid and then perform molecular analyses on these cells. We evaluated 85 putative ovarian cancer protein markers and found that nearly two-thirds were either nonspecific for malignant disease or had low abundance. Using four of the most promising markers, we prospectively studied 47 patients (33 ovarian cancer and 14 control)."
According to the news reporters, the research concluded: "We show that a marker set (ATC(dx)) can sensitively and specifically map ATC numbers and, through its reliable enrichment, facilitate additional treatment-response measurements related to proliferation, protein translation, or pathway inhibition."
For more information on this research see: Ascites analysis by a microfluidic chip allows tumor-cell profiling. Proceedings of the National Academy of Sciences of the United States of America, 2013;110(51):E4978-E4986. Proceedings of the National Academy of Sciences of the United States of America can be contacted at: Natl Acad Sciences, 2101 Constitution Ave NW, Washington, DC 20418, USA. (National Academy of Sciences - www.nasonline.org/; Proceedings of the National Academy of Sciences of the United States of America - www.nasonline.org/publications/pnas/)
Our news journalists report that additional information may be obtained by contacting V.M. Peterson, MIT, Cambridge, MA 02139, United States. Additional authors for this research include C.M. Castro, J. Chung, N.C. Miller, A.V. Ullal, M.D. Castano, R.T. Penson, H. Lee, M.J. Birrer and R. Weissleder (see also Ascites).
Keywords for this news article include: Cancer, Ascites, Oncology, Cambridge, Treatment, Massachusetts, United States, North and Central America, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC